Jeffrey Paccione, MD
Retina Specialist · Elmhurst, NYNPI 1467446575
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,580 of the $16,654 with a category attached, or 87.5%. Bayer accounts for 87.5% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $8,640 and has fallen 94.0% since, to $523 in 2025.
Across 74 payments — averaging $225.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$15K
- Regeneron Healthcare Solutions, Inc.$744
- Astellas Pharma US Inc$347
- AbbVie$272
- Genentech USA, Inc.$248
- Coherus Oncology, Inc.$144
- plus $320 from 7 others
Across 7 payments — averaging $11,070 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$77K
What the payments were for
- Consulting fees$14,58088%
- Food & beverage$2,07412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 8 | $14,580 |
| Regeneron Healthcare Solutions, Inc. | 24 | $744 |
| Astellas Pharma US Inc | 11 | $347 |
| AbbVie | 9 | $272 |
| Genentech USA, Inc. | 10 | $248 |
| Coherus Oncology, Inc. | 4 | $144 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| ANI Pharmaceuticals, Inc. | 2 | $63 |
| Sandoz | 1 | $48 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $23 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
| Akorn Operating Company LLC | 1 | $20 |
| Biogen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered$14,580
- EYLEA HD$351
- ACTHAR$125
- Izervay$108
How this compares
$16,654 in reported general payments places this provider in the 85th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 750 | $15,984 |
| ProlensaBromfenac Sodium | 31 | $14,789 |
| Bromfenac Sodium | 24 | $2,605 |
| Loteprednol Etabonate | 16 | $2,492 |
| Prednisolone Acetate | 51 | $2,469 |
| Dorzolamide Hcl | 87 | $1,188 |
| Diclofenac Sodium | 19 | $286 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $214 |
| Latanoprost | 21 | $99 |
| Timolol Maleate | 12 | $91 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Elmhurst
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
- Mark BreazzanoLiverpool$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.